Arizona’s Family Investigates went to the Scottsdale lab, the only one in the country authorized by the DEA to grow the ...

The project, funded by the inaugural Trinity-SwRI Research Collaboration Program, is developing a formulation for intranasal ...

Ohio lawmakers are exploring the possibility of using a psychedelic drug to treat patients with severe addictions or ...

Southwest Research Institute (SwRI) and Trinity University are developing an intranasal (IN) drug-device combination to treat ...

A new report examining behavioral health trends in Virginia has found a significant five-year increase in hospital admissions for depression, PTSD, drug use and autism spectrum disorder. Virginia ...

Celltrion is buying an Eli Lilly drug substance plant in the U.S. for $330 million. The FDA has declined to approve Lundbeck and Otsuka's Rexulti in PTSD. Hengrui Pharma has out-licensed certain ...

About 12 million adults in the United States are affected by PTSD, impacting between 4% and 8% of the adult population – and up to 30% of military personnel and veterans. Strikingly, 63% of veterans ...

About 12 million adults in the United States are affected by PTSD, impacting between 4% and 8% of the adult population – and up to 30% of military personnel and veterans. Strikingly, 63% of veterans ...

SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, ...

An experimental drug reverses PTSD-like symptoms in mice. The corresponding study was published in Signal Transduction and Targeted Therapy and may pave the way for a new treatment for PTSD. “This ...

FDA's outside experts weren't sold on the trial data for brexpiprazole (Rexulti) as an adjunctive treatment for post-traumatic stress disorder (PTSD), sinking its prospects for approval in this ...